MedPath

Sulfur hexafluoride

Generic Name
Sulfur hexafluoride
Brand Names
Lumason, Sonovue, SonoVue
Drug Type
Small Molecule
Chemical Formula
F6S
CAS Number
2551-62-4
Unique Ingredient Identifier
WS7LR3I1D6
Background

Sulfur hexafluoride is an ultrasound contrast agent indicated for use

•in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms

•in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

Indication

Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border.

Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.

Associated Conditions
-
Associated Therapies
-

Preterm Neonates Brain Ultrasound With CEUS and Elastography

Phase 3
Recruiting
Conditions
Prematurity
Interventions
Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography
Drug: Sulfur Hexafluoride
First Posted Date
2023-01-23
Last Posted Date
2024-10-15
Lead Sponsor
Turku University Hospital
Target Recruit Count
100
Registration Number
NCT05694611
Locations
🇫🇮

Turku University Hospital, Turku, Southwestern Finland, Finland

Neonatal Brain Ultrasound With CEUS and Elastography

Phase 3
Recruiting
Conditions
Neonatal Hypoxic Ischemic Encephalopathy
Neonatal Stroke
Neonatal Encephalopathy, Unspecified
Interventions
Diagnostic Test: Brain contrast enhanced ultrasound, brain ultrasound elastography
Drug: Sulfur Hexafluoride
First Posted Date
2022-12-13
Last Posted Date
2024-10-15
Lead Sponsor
Turku University Hospital
Target Recruit Count
100
Registration Number
NCT05648812
Locations
🇫🇮

Turku University Hospital, Turku, Southwestern Finland, Finland

Ultrasound Evaluation of Crohn's Disease

Phase 4
Terminated
Conditions
Crohn Disease
Interventions
Drug: Sulfur Hexafluoride
Device: Ultrasound Elastography
Device: Ultrasound Vascularity
Device: Magnetic Resonance Enterography (MRE)
First Posted Date
2017-08-01
Last Posted Date
2021-11-10
Lead Sponsor
Mayo Clinic
Target Recruit Count
9
Registration Number
NCT03235180
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

The Silicone Study

Phase 3
Completed
Conditions
Proliferative Vitreoretinopathy
Retinal Detachment
First Posted Date
1999-09-24
Last Posted Date
2005-06-24
Lead Sponsor
National Eye Institute (NEI)
Registration Number
NCT00000140
© Copyright 2025. All Rights Reserved by MedPath